nature.com

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis - Bone Marrow Transplantation

  • ️Skinner, M
  • ️Thu Nov 01 2001
  • Mini Review
  • Published: 01 November 2001

Mini-review

Bone Marrow Transplantation volume 28, pages 637–642 (2001)Cite this article

Abstract

Primary or AL amyloidosis results from a plasma cell dyscrasia in which fibrillar light chain protein deposition leads to organ failure and death. Standard treatment for AL amyloidosis has been oral melphalan and prednisone. However, this form of treatment modifies the natural history of this lethal disease only marginally, extending median survival from 13 months following diagnosis to 17 months. At Boston University Medical Center, we have developed treatment protocols using high-dose intravenous melphalan with autologous peripheral blood stem cell transplantation (HDM/SCT) to treat AL amyloidosis, and we have treated over 200 patients with HDM/SCT during the past six years. This extensive experience has shown that patients with AL amyloidosis, despite multisystem involvement and compromised organ function can tolerate this aggressive form of treatment. Furthermore, HDM/SCT results in durable hematologic responses in a substantial proportion of patients, and such responses are associated with clinical improvement, decreased amyloid-related organ dysfunction, and prolonged survival. However, toxicity from treatment is high (overall peri-transplant mortality, 14%), particularly for those patients with clinically significant cardiac involvement. For this reason, we believe a multidisciplinary management approach is essential when using HDM/SCT for treatment of AL amyloidosis. Based on our experience, we believe that HDM/SCT is the treatment of choice for patients with AL amyloidosis who have a good performance status and limited cardiac involvement at the time of diagnosis. HDM/SCT offers the best chance for hematologic remission, prolongation of survival, and reversal of amyloid-related disease. At the same time, we believe that HDM/SCT should continue to be examined in the context of clinical trials, directed at developing approaches to broaden the applicability of this therapy by minimizing toxicity and to increase the likelihood of complete hematologic responses. Bone Marrow Transplantation (2001) 28, 637–642.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Falk RH, Comenzo RL, Skinner M . The systemic amyloidoses New Engl J Med 1997 337: 898–909

    Article  CAS  PubMed  Google Scholar 

  2. Kyle RA, Gertz MA . Primary systemic amyloidosis: clinical and laboratory features in 474 cases Semin Hematol 1995 32: 45–59

    CAS  PubMed  Google Scholar 

  3. Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis Blood 1999 93: 1062–1066

    CAS  PubMed  Google Scholar 

  4. Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone and colchicine versus colchicine only Am J Med 1996 100: 290–298

    Article  CAS  PubMed  Google Scholar 

  5. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine New Engl J Med 1997 336: 1202–1207

    Article  CAS  PubMed  Google Scholar 

  6. Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis J Clin Oncol 1999 17: 262–267

    Article  CAS  PubMed  Google Scholar 

  7. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–95

    Article  CAS  PubMed  Google Scholar 

  8. Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients Blood 1996 88: 2801–2806

    CAS  PubMed  Google Scholar 

  9. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients Blood 1998 91: 3662–3670

    CAS  PubMed  Google Scholar 

  10. Sanchorawala V, Wright DG, Dember LM et al. Five years experience with high dose intravenous melphalan and autologous peripheral blood stem cell transplantation for the treatment of patients with AL amyloidosis Blood 1999 94: 396a

    Google Scholar 

  11. Dember LM, Sanchorawala V, Seldin DC et al. Effect of dose-intensive intravenous melphalan and autologous blood stem cell transplant on AL amyloidosis-associated renal disease Ann Intern Med 2001 134: 746–753

    Article  CAS  PubMed  Google Scholar 

  12. Choufani E, Sanchorawala V, Skinner M et al. Acquired factor X deficiency in patients with AL amyloidosis: incidence, bleeding manifestations, and response to high dose therapy Blood 2001 96: 1885–1887

    Article  Google Scholar 

  13. Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) Bone Marrow Transplant 2000 26: 963–969

    Article  CAS  PubMed  Google Scholar 

  14. Gertz MA, Lacy MQ, Dispenzieri A . Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report Bone Marrow Transplant 2000 25: 465–470

    Article  CAS  PubMed  Google Scholar 

  15. Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients Br J Haematol 1998 101: 766–769

    Article  CAS  PubMed  Google Scholar 

  16. Gillmore JD, Apperley JF, Craddock C et al. High-dose melphalan and stem cell rescue for AL amyloidosis. VIII International Symposium on Amyloidosis. Mayo Clinic: Rochester, MN. August 7–11, 1998 p 102

  17. Saba N, Tsang R, Sutton DM et al. High treatment-related mortality in cardaic amyloid patients supports the use of less intensive, non-cardiotoxic PBSC collection and induction regimens Blood 1998 10: (Suppl. 1) 660a

    Google Scholar 

  18. Dispenzieri A, Lacy MQ, Kyle RA et al. AL amyloidosis is a favorable independent prognostic factor for survival of 234 patients with primary systemic amyloidosis (AL) functionally eligible for peripheral blood stem cell transplantation Proc ASCO 1999 18: 20a

    Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the numerous current and former colleagues in the Stem Cell Transplant Program, Amyloid Research and Treatment Program, Clinical Trials Office, and Clinical Laboratories at Boston Medical Center who have assisted with the multidisciplinary evaluation and treatment of patients with AL amyloidosis. This work was supported in part by grants from the Food and Drug Administration FD-R-001346 and from the Gerry Foundation. Dr Seldin is a scholar of the Leukemia and Lymphoma Society of America.

Author information

Authors and Affiliations

  1. Stem Cell Transplant Program of the Section of Hematology and Oncology, Boston University School of Medicine, Boston University Medical Center, Boston, MA, USA

    V Sanchorawala, DG Wright, DC Seldin, K Finn & K Quillen

  2. Amyloid Research and Treatment Program, Boston University School of Medicine, Boston University Medical Center, Boston, MA, USA

    V Sanchorawala, DG Wright, DC Seldin, LM Dember, K Finn, RH Falk, J Berk, K Quillen & M Skinner

  3. Amyloid Research and Treatment Program, Section of Renal Medicine, Boston University School of Medicine, Boston University Medical Center, Boston, MA, USA

    LM Dember

  4. Amyloid Research and Treatment Program, Section of Cardiology, Boston University School of Medicine, Boston University Medical Center, Boston, MA, USA

    RH Falk

  5. Amyloid Research and Treatment Program, Section of Pulmonology, Boston University School of Medicine, Boston University Medical Center, Boston, MA, USA

    J Berk

  6. Section of Rheumatology in the Department of Medicine, Amyloid Research and Treatment Program, Boston University School of Medicine, Boston University Medical Center, Boston, MA, USA

    M Skinner

Authors

  1. V Sanchorawala

    You can also search for this author inPubMed Google Scholar

  2. DG Wright

    You can also search for this author inPubMed Google Scholar

  3. DC Seldin

    You can also search for this author inPubMed Google Scholar

  4. LM Dember

    You can also search for this author inPubMed Google Scholar

  5. K Finn

    You can also search for this author inPubMed Google Scholar

  6. RH Falk

    You can also search for this author inPubMed Google Scholar

  7. J Berk

    You can also search for this author inPubMed Google Scholar

  8. K Quillen

    You can also search for this author inPubMed Google Scholar

  9. M Skinner

    You can also search for this author inPubMed Google Scholar

About this article

Cite this article

Sanchorawala, V., Wright, D., Seldin, D. et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28, 637–642 (2001). https://doi.org/10.1038/sj.bmt.1703200

Download citation

  • Published: 01 November 2001

  • Issue Date: 01 October 2001

  • DOI: https://doi.org/10.1038/sj.bmt.1703200

Keywords